New hope for Drug-Resistant TB: a 6-Month pill regimen

NCT ID NCT06649721

Ongoing Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial is testing a 6-month, all-oral combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine) to treat rifampin-resistant tuberculosis in Chinese teenagers and adults aged 12 and older. The goal is to see if this shorter regimen is effective and safe. 120 participants will take the pills and be followed for up to 72 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of bedaquiline, delamanid, linezolid, and levofloxacin or clofazimine
What this could lead to: If successful, this could offer a shorter, all-oral treatment option for drug-resistant tuberculosis, reducing treatment time and side effects.
What could go wrong: This is a single-arm trial with no comparison group, so results may be less reliable. Side effects from the drugs can be serious, and the regimen may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug-resistant tuberculosis multidrug-resistant tuberculosis pulmonary tuberculosis rifampicin-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG-RESISTANT TUBERCULOSIS PULMONARY TUBERCULOSIS RIFAMPIN-RESISTANT TUBERCULOSIS

Contacts and locations

Locations

Anhui Chest Hospital

Hefei, Anhui, China
Beijing Chest Hospital

Beijing, China
Changsha Central Hospital

Changsha, Hunan, China
Harbin Chest Hospital

Harbin, Helongjiang, China
Hebei Chest Hospital

Shijiazhuang, Hebei, China
Henan Chest Hospital

Zhengzhou, Henan, China
Henan Infectious Disease Hospital

Zhengzhou, Henan, China
Huashan Hospital

Shanghai, China
Hulunbuir Infectious Disease Hospital

Hulunbuir, Inner Mongolia, China
Infectious Disease Hospital of Changchun

Changchun, Jilin, China
Infectious Disease Hospital of Heilongjiang Province

Harbin, Heilongjiang, China
Jiamusi Tuberculosis Hospital(Jiamusi Cancer Hospital)

Jiamusi, Heilongjiang, China
Jiangxi Chest Hospital

Nanchang, Jiangxi, China
Jilin Tuberculosis Hospital

Jilin City, Jilin, China
Linyi People Hospital

Linyi, Shandong, China
Liupanshui Third People's Hospital

Liupanshui, Guizhou, China
Luoyang Center Hospital

Luoyang, Henan, China
Public Health Clinical Center of Chengdu

Chengdu, Sichuan, China
Qingdao Chest Hospital

Qingdao, Shandong, China
Shandong Public Health Clinical Center, Shandong University

Jinan, Shandong, China
Shanxi Medical University Affiliated Chest Hospital

Taiyuan, Shanxi, China
Shenyang Chest Hospital

Shenyang, Liaoning, China
The 8th Medical Center of Chinese PLA General Hospital

Beijing, Beijing Municipality, China
The Fifth Hospital of Shijiazhuang

Shijiazhuang, Hebei, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China
The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China
The Fourth People's Hospital of Nanning

Nanning, Guangxi, China
The Second Hospital of Nanjing

Nanjing, Jiangsu, China
Tianjin Haihe Hospital

Tianjin, Tianjin Municipality, China
Weifang No.2 People's Hospital

Weifang, Shandong, China
Wenzhou Central Hospital

Wenzhou, Zhejiang, China
Wuhan Pulmonary Hospital，Wuhan Tuberculosis Prevention and Control Institute

Wuhan, Hubei, China
Xi'an Chest Hospital

Xi'an, Shaanxi, China
Yantai Qishan Hospital

Yantai, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.